Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 15/20 | 0.74 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476569 | 0.86 | MEN1 (0.62) | TAS2R14FABP4PTGS1AKR1C3AKR1C2 | |
| SCHEMBL23691078 | 0.86 | TAS2R14 (0.74) | TAS2R14FABP4PTGS1AKR1C3AKR1C2 | |
| SCHEMBL11338181 | 0.85 | TAS2R14 (0.72) | TAS2R14FABP4PTGS1AKR1C3AKR1C2 | |
| SCHEMBL12697392 | 0.84 | TAS2R14 (0.54) | TAS2R14AKR1C3AKR1C2MPO | |
| SCHEMBL6482325 | 0.82 | TAS2R14 (0.53) | TAS2R14FABP4PTGS1AKR1C3AKR1C2 | |
| SCHEMBL2625434 | 0.80 | TAS2R14 (0.65) | TAS2R14FABP4PTGS1AKR1C3AKR1C2 | |
| SCHEMBL4245559 | 0.78 | MAPK8 (0.67) | TAS2R14FABP4PTGS1AKR1C3AKR1C2 | |
| SCHEMBL1358523 | 0.77 | TAS2R14 (0.75) | TAS2R14FABP4AKR1C3AKR1C2CLCN2 | |
| Flufenamic Acid SCHEMBL17497 | 0.77 | RXFP1 (0.75) | TAS2R14PTGS1AKR1C3AKR1C2PTGS2 | |
| Flufenamic Acid SCHEMBL29356958 | 0.77 | RXFP1 (0.75) | TAS2R14PTGS1AKR1C3AKR1C2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | claimed |
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | CLIC1, ASIC1, CLIC4 | TAS2R14 1778/4885FABP4 1600/4885PTGS1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.